# OnCo record nct07208539 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07208539/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07208539", "NCT07208539" ;
  schema:name "AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer."@en ;
  schema:alternateName "ZSPAC-14"@en ;
  schema:description "A phase 2 trial in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07208539/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07208539> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/> .